Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Common Equity (2016 - 2025)

Nephros (NEPH) has 16 years of Common Equity data on record, last reported at $10.0 million in Q3 2025.

  • For Q3 2025, Common Equity rose 22.41% year-over-year to $10.0 million; the TTM value through Sep 2025 reached $10.0 million, up 22.41%, while the annual FY2024 figure was $8.6 million, 2.72% up from the prior year.
  • Common Equity reached $10.0 million in Q3 2025 per NEPH's latest filing, up from $9.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $15.5 million in Q1 2021 and bottomed at $7.9 million in Q2 2024.
  • Average Common Equity over 5 years is $10.6 million, with a median of $9.3 million recorded in 2025.
  • Peak YoY movement for Common Equity: skyrocketed 34.0% in 2021, then plummeted 39.79% in 2022.
  • A 5-year view of Common Equity shows it stood at $14.7 million in 2021, then tumbled by 39.79% to $8.9 million in 2022, then dropped by 5.89% to $8.4 million in 2023, then grew by 2.72% to $8.6 million in 2024, then increased by 16.55% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $10.0 million in Q3 2025, $9.6 million in Q2 2025, and $9.3 million in Q1 2025.